Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 63 Records) |
| Query Trace: Lung Neoplasms and KEAP1[original query] |
|---|
| KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials. Frontiers in oncology 2021 11 659200. Zhu Hongyuan, Xie Daipeng, Yu Yunfang, Yao Lintong, Xu Bin, Huang Luyu, Wu Shaowei, Li Fasheng, Zheng Yating, Liu Xinyi, Xie Wenzhuan, Huang Mengli, Li Hao, Zheng Shaopeng, Zhang Dongkun, Qiao Guibin, Chan Lawrence W C, Zhou Hai |
| Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases. Molecular brain 2021 12 14 (1): 176. Xu Yanjun, Huang Zhiyu, Yu Xiaoqing, Chen Kaiyan, Fan Y |
| Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Nov . Ricciuti Biagio, Arbour Kathryn C, Lin Jessica J, Vajdi Amir, Vokes Natalie, Hong Lingzhi, Zhang Jianjun, Tolstorukov Michael Y, Li Yvonne Y, Spurr Liam F, Cherniack Andrew D, Recondo Gonzalo, Lamberti Giuseppe, Wang Xinan, Venkatraman Deepti, Alessi Joao V, Vaz Victor R, Rizvi Hira, Egger Jacklynn, Plodkowski Andrew J, Khosrowjerdi Sara, Digumarthy Subba, Park Hyesun, Vaz Nuno, Nishino Mizuki, Sholl Lynette M, Barbie David, Altan Mehmet, Heymach John V, Skoulidis Ferdinandos, Gainor Justin F, Hellmann Matthew D, Awad Mark |
| Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical lung cancer 2021 Oct . Hellyer Jessica A, White Maya N, Gardner Rebecca M, Cunanan Kristen, Padda Sukhmani K, Das Millie, Ramchandran Kavitha, Neal Joel W, Wakelee Heather |
| Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 10 17 (1): 76-88. Saleh Mohamed Mahde, Scheffler Matthias, Merkelbach-Bruse Sabine, Scheel Andreas Hans, Ulmer Bastian, Wolf Jürgen, Buettner Reinha |
| Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer. Free radical biology & medicine 2021 Oct 177 58-71. Delgobo Marina, Gonçalves Rosângela Mayer, Delazeri Marco Antônio, Falchetti Marcelo, Zandoná Alessandro, Nascimento das Neves Raquel, Almeida Karoline, Fagundes Adriane Cristina, Gelain Daniel Pens, Fracasso João Isidro, Macêdo Guilherme Baroni de, Priori Leonardo, Bassani Nicklas, Bishop Alexander James Roy, Forcelini Cassiano Mateus, Moreira José Cláudio Fonseca, Zanotto-Filho Alf |
| Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Toxicity and Efficacy in Non-Small-Cell Lung Cancer. International journal of radiation oncology, biology, physics 2021 Nov 111 (3S): e437. He K, Zhang S, Pang J, Yin J, Zhang J, Mu D, Tang S, Li L, Bao H, Wu X, Wang X, Shao Y, Yu J, Yuan |
| Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer. Frontiers in oncology 2022 12 928605. He Kewen, Zhang Shaotong, Pang Jiaohui, Yin Jiani C, Mu Dianbin, Wang Jun, Ge Hong, Ma Jie, Yang Zhe, Zheng Xiaoli, Dong Lihua, Zhang Junli, Chang Pengyu, Li Li, Tang Shanshan, Bao Hua, Wu Xue, Wang Xiaonan, Shao Yang, Yu Jinming, Yuan Shuang |
| Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer. Journal of thoracic disease 2022 7 14 (6): 1772-1783. Malhotra Jyoti, Ryan Brid, Patel Malini, Chan Nancy, Guo Yanxiang, Aisner Joseph, Jabbour Salma K, Pine Shar |
| STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Lung cancer (Amsterdam, Netherlands) 2022 Jun 170 114-121. Cordeiro de Lima Vladmir C, Corassa Marcelo, Saldanha Erick, Freitas Helano, Arrieta Oscar, Raez Luis, Samtani Suraj, Ramos Maritza, Rojas Carlos, Burotto Mauricio, Chamorro Diego F, Recondo Gonzalo, Ruiz-Patiño Alejandro, Más Luis, Zatarain-Barrón Lucia, Mejía Sergio, Nicolas Minata José, Martín Claudio, Bautista Blaquier Juan, Motta Guerrero Rodrigo, Aliaga-Macha Carlos, Carracedo Carlos, Ordóñez-Reyes Camila, Garcia-Robledo Juan Esteban, Corrales Luis, Sotelo Carolina, Ricaurte Luisa, Santoyo Nicolas, Cuello Mauricio, Jaller Elvira, Rodríguez July, Archila Pilar, Bermudez Maritza, Gamez Tatiana, Russo Alessandro, Viola Lucia, Malapelle Umberto, de Miguel Perez Diego, Rolfo Christian, Rosell Rafael, Cardona Andrés |
| Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database. Clinical lung cancer 2022 6 23 (6): 487-497. Wu Yanyu, Yin Yu, Crossland Victoria, Vincent Sylvie, Paik Paul K, Lineberry Neil, Faller Douglas |
| Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. The oncologist 2022 May . Huang Richard S P, Harries Lukas, Decker Brennan, Hiemenz Matthew C, Murugesan Karthikeyan, Creeden James, Tolba Khaled, Stabile Laura P, Ramkissoon Shakti H, Burns Timothy F, Ross Jeffrey |
| The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer. Cancer medicine 2022 4 11 (19): 3581-3592. Chen Hanxiao, Huang Dingzhi, Lin Gen, Yang Xue, Zhuo Minglei, Chi Yujia, Zhai Xiaoyu, Jia Bo, Wang Jingjing, Wang Yuyan, Li Jianjie, An Tongtong, Wu Meina, Wang Ziping, Zhao J |
| Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma. Journal of Cancer 2022 4 13 (5): 1565-1572. Wu Xiaonan, Zhao Jun, Yang Ling, Nie Xin, Wang Zheng, Zhang Ping, Li Chao, Hu Xueqing, Tang Min, Yi Yuting, Du Xinhua, Xia Xuefeng, Guan Yanfang, Yu Zicheng, Gu Wenguang, Quan Xiangming, Li Lin, Shi Ho |
| Landscape of KRAS, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO precision oncology 2022 3 6 e2100245. Salem Mohamed E, El-Refai Sherif M, Sha Wei, Puccini Alberto, Grothey Axel, George Thomas J, Hwang Jimmy J, O'Neil Bert, Barrett Alexander S, Kadakia Kunal C, Musselwhite Laura W, Raghavan Derek, Van Cutsem Eric, Tabernero Josep, Tie Jean |
| KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously". Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 2 17 (3): e40-e41. Scalera Stefano, Mazzotta Marco, Cappuzzo Federico, Ciliberto Gennaro, Maugeri-Saccà Marcel |
| Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. Journal for immunotherapy of cancer 2022 02 10 (2): . West Howard Jack, McCleland Mark, Cappuzzo Federico, Reck Martin, Mok Tony Sk, Jotte Robert M, Nishio Makoto, Kim Eugene, Morris Stefanie, Zou Wei, Shames David, Das Thakur Meghna, Shankar Geetha, Socinski Mark |
| Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component. Frontiers in oncology 2022 12 12 989349. Li Peng, Liu Lu, Wang Dong, Yang Ronghua, Xuan Yunpeng, Han Yudong, Wang Jinglong, Guo Lijie, Zhang Liwen, Zhang Shanshan, Wang Yongj |
| Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 10 . Paik Paul K, Fan Pang-Dian, Qeriqi Besnik, Namakydoust Azadeh, Daly Bobby, Ahn Linda, Kim Rachel, Plodkowski Andrew, Ni Ai, Chang Jason, Fanaroff Rachel, Ladanyi Marc, de Stanchina Elisa, Rudin Charles |
| Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO precision oncology 2022 1 5 153-162. Padda Sukhmani K, Aredo Jacqueline V, Vali Shireen, Singh Neeraj K, Vasista Sumanth M, Kumar Ansu, Neal Joel W, Abbasi Taher, Wakelee Heather |
| Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma. Frontiers in oncology 2022 1 11 664397. Chen Ying, Cui Xiaoying, Wang Di, Xia Guojie, Xing Minyan, Cheng Lei, Sheng Liming, Du Xiangh |
| The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC. Genes & diseases 2022 1 9 (1): 245-251. Wang Shuhang, Jiang Miaomiao, Yang Zuozhen, Huang Xiaoyun, Li Ni |
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022 Jun . Cortellini Alessio, Ricciuti Biagio, Borghaei Hossein, Naqash Abdul Rafeh, D'Alessio Antonio, Fulgenzi Claudia A M, Addeo Alfredo, Banna Giuseppe L, Pinato David Jam |
| Probing Mutant KRAS, STK11, KEAP1 in NSCLC. Cancer discovery 2022 Aug OF1. Authors are not available |
| Coexisting Genomic Alterations in Risk Stratification of KRASG12C-Mutated Non-Small Cell Lung Cancer. Cancer discovery 2023 7 13 (7): 1513-1515. Sarina Z W Heng, Regina Hoo, Daniel S W T |
| Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting. BMC cancer 2023 4 23 (1): 352. Julian Cristina, Pal Navdeep, Gershon Anda, Evangelista Marie, Purkey Hans, Lambert Peter, Shi Zhen, Zhang Qi |
| Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer. Internal medicine (Tokyo, Japan) 2023 3 . Sumii Masahiko, Namba Masashi, Tokumo Kentaro, Yamauchi Masami, Okamoto Wataru, Hattori Noboru, Sugiyama Kazuhi |
| Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023 2 . Rao Wen, Yang Lujie, Dai Nan, Zhang Liang, Liu Jie, Yang Bo, Li Mengxia, Shan Jinlu, Wang Qiushi, Wang Do |
| Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab. JAMA network open 2023 1 6 (1): e2249591. Lebow Emily S, Shepherd Annemarie, Eichholz Jordan E, Offin Michael, Gelblum Daphna Y, Wu Abraham J, Simone Charles B, Schoenfeld Adam J, Jones David R, Rimner Andreas, Chaft Jamie E, Riaz Nadeem, Gomez Daniel R, Shaverdian Nar |
| Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology 2023 1 . Mok T S K, Lopes G, Cho B C, Kowalski D M, Kasahara K, Wu Y-L, de Castro G, Turna H Z, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza M C, Piperdi B, Herbst R |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 18, 2023
- Content source: